Pdt Partners, LLC Esperion Therapeutics, Inc. Transaction History

Pdt Partners, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$5.09 - $8.5 $93,447 - $156,051	-18,359 Reduced 38.95%	28,779 $179,000
Q3 2022 Nov 14, 2022	SELL	$5.45 - $8.13 $494,505 - $737,675	-90,735 Reduced 65.81%	47,138 $316,000
Q2 2022 Aug 15, 2022	SELL	$4.77 - $6.67 $173,828 - $243,068	-36,442 Reduced 20.91%	137,873 $877,000
Q1 2022 May 16, 2022	SELL	$3.34 - $5.56 $222,176 - $369,851	-66,520 Reduced 27.62%	174,315 $809,000
Q4 2021 Feb 14, 2022	BUY	$4.81 - $11.92 $577,233 - $1.43 Million	120,007 Added 99.32%	240,835 $1.2 Million
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $186,293 - $351,066	16,428 Added 15.74%	120,828 $1.46 Million
Q2 2021 Aug 16, 2021	BUY	$19.4 - $28.71 $1.7 Million - $2.52 Million	87,622 Added 522.24%	104,400 $2.21 Million
Q1 2021 May 17, 2021	BUY	$25.12 - $36.89 $421,463 - $618,940	16,778 New	16,778 $471,000
Q3 2020 Nov 16, 2020	SELL	$31.18 - $52.71 $2.87 Million - $4.86 Million	-92,200 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$30.04 - $51.31 $341,464 - $583,240	-11,367 Reduced 10.98%	92,200 $4.73 Million
Q1 2020 May 15, 2020	BUY	$27.44 - $73.84 $937,542 - $2.52 Million	34,167 Added 49.23%	103,567 $3.27 Million
Q4 2019 Feb 14, 2020	BUY	$35.4 - $59.82 $180,327 - $304,723	5,094 Added 7.92%	69,400 $4.14 Million
Q3 2019 Nov 14, 2019	SELL	$34.47 - $47.53 $1,137 - $1,568	-33 Reduced 0.05%	64,306 $2.36 Million
Q2 2019 Aug 14, 2019	BUY	$40.1 - $52.33 $2.58 Million - $3.37 Million	64,339 New	64,339 $2.99 Million

207

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $171M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.